Analysis of liver cancer development in patients who showed sustained viral response to chronic hepatitis C virus infection by receiving direct acting-antiviral therapy, a prospective multicenter study
Not Applicable
- Conditions
- Hepatitis C virus-related chronic liver diseases
- Registration Number
- JPRN-UMIN000027988
- Lead Sponsor
- Kurume University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 3011
Inclusion Criteria
Not provided
Exclusion Criteria
1) (Potentially) pregnant woman and lactating woman 2) Allergic reaction for DAAs and biological agents including vaccines 3) Difficult-to-control heart diseases 4) Severe liver injury, including Child-Pugh class B and C 5) Contraindicated drugs for combination with DAAs 6) Uncontrolled diabetes mellitus 7) Inappropriate patients who are judged by study-managing doctors
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Characteristics of liver cancer developed after DAA-induced SVR (tumor size, number of tumor, gross appearance, location, vascular invasion, and tumor markers)
- Secondary Outcome Measures
Name Time Method 1) Patient characteristics and background liver when liver caner occurs 2) Liver cancer incidence 3)Possible inhibitory effect of SVR on liver cancer recurrence in patients receiving curative therapy for primary liver cancer 4) Patients' prognosis 5) Adverse effects of DAA treatments